All In Biotech

Free tool

FAERS Monitor: Erivedge

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 203388 or its brand name (Erivedge, Vismodegib). Reports on generic versions are filed under their own applications.

Reports

8,927

Serious

3,811

43% of reports

Hospitalization

1,151

Death reported

998

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • muscle spasms2,074
  • alopecia1,406
  • ageusia1,018
  • fatigue980
  • death757
  • dysgeusia748
  • weight decreased741
  • nausea722
  • decreased appetite708
  • diarrhoea476
  • constipation383
  • off label use383
  • asthenia295
  • arthralgia284
  • no adverse event262

Reports by year received

View as table
YearReports
20101
20113
2012122
2013241
2014292
2015468
2016631
20171,465
2018869
2019773
2020710
2021663
2022741
2023674
2024666
2025385
2026223

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,045,232 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
ageusiaSignal1,018100.294.495,917
muscle spasmsSignal2,07426.925.951,601
dysgeusiaSignal74824.022.416,322
alopeciaSignal1,40617.016.221,179
decreased appetiteSignal7087.26.73,805
weight decreasedSignal7416.35.83,311
constipationSignal3834.13.8918
no adverse eventSignal2623.43.0447
fatigueSignal9803.02.81,324
nauseaSignal7222.22.0460
deathSignal7572.11.9436
asthenia2951.81.7116
diarrhoea4761.71.6153
arthralgia2841.61.466
off label use3831.00.90

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.